Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome
|
|
- Felicity Wilkinson
- 5 years ago
- Views:
Transcription
1 Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D., a Bart C. J. M. Fauser, M.D., Ph.D., b Joop S. E. Laven, MD, Ph.D., c Marinus J. Eijkemans, Ph.D., b and Fulco van der Veen, M.D., Ph.D. a a Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; b Department of Reproductive Medicine and Gynecology, University Medical Center, Utrecht, The Netherlands; and c Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands Objective: To validate a published model for the prediction of the individual FSH response dose for gonadotropin induction of ovulation in polycystic ovary syndrome (PCOS). Design: Structured, complete, and carefully monitored patient-based data collection to test the external validity of the prediction model. Setting: Twenty-nine hospitals in The Netherlands. Patient(s): Eighty-five clomiphene citrate (CC) resistant women with PCOS. Intervention(s): Ovulation induction in a chronic low-dose step-up FSH regimen. Main Outcome Measure(s): Predicted individual FSH response dose, defined as follicle growth 10 mm in diameter on ultrasound. Result(s): The model, using the women s body mass index, CC response, initial serum FSH level, and initial serum insulin-to-glucose ratio was studied in the validation sample. Overall, the FSH response dose predicted by the model was higher than the observed response dose. The predictive performance of the model was poor, with an R 2 of 0.11, and the average prediction error was 35 IU. Conclusion(s): The external validity of the model predicting the individual FSH response dose was inadequate in women with CC-resistant PCOS undergoing ovulation induction with recombinant FSH in a low-dose step-up regimen. (Fertil Steril 2006;86: by American Society for Reproductive Medicine.) Key Words: Validation, ovulation induction, PCOS, rfsh Polycystic ovary syndrome (PCOS) is the commonest cause of anovulatory infertility and is estimated to affect approximately 6% 7% of women in the general population (1 4). Clomiphene citrate (CC) still represents the first-line treatment of choice in women with PCOS, although approximatetely 20% 25% of the women do not ovulate and over 50% do not conceive after CC (5, 6). Women not responding to CC represent a clinical challenge. In these CC-resistant women, ovulation induction with gonadotropins is standard treatment. Pregnancy rates between 35% and 70% after ovulation induction with FSH have been reported in the literature (7 9). Ovulation induction with FSH is, especially in PCOS, also associated with a high risk of multiple pregnancies caused by multiple follicular development (10 12). For this reason, adjusted dose regimens and intense monitoring of ovarian response to prevent multiple follicular development have been implemented. Received January 26, 2006; revised and accepted May 8, Reprint requests: Madelon van Wely, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Meibergdreef 9, 1109 AZ Amsterdam, The Netherlands (FAX: ; m. vanwely@amc.uva.nl). The amount of exogenous FSH required to induce ovulation varies greatly, because the individual FSH threshold differs among individual women (13). This variability is considered responsible for the high incidence of complications caused by the development of multiple dominant follicles, which may result in multiple pregnancies and ovarian hyperstimulation syndrome (14, 15). One method of finetuning FSH levels and reducing complications is to start with a low dose of FSH and gradually increase the dose until ovarian response is observed. Such an approach is referred to as the chronic low-dose step-up regimen. Another treatment strategy is the step-down regimen, which involves a relatively high initial dose of FSH followed by subsequent stepwise decreases (16 18). This approach more closely mimics physiologic conditions in normo-ovulatory women (19). However, the initial standard FSH dose may be too high for those women with a low FSH threshold level and could induce imminent ovarian hyperstimulation, requiring cancelation of stimulation. Adjustment of the starting dose in women with a low FSH threshold would reduce the incidence of multiple dominant follicle development and related complications during the step-down regimen. The ability of clinicians to choose an appropriate starting dose of FSH for a given patient could considerably improve 1710 Fertility and Sterility Vol. 86, No. 6, December /06/$32.00 Copyright 2006 American Society for Reproductive Medicine, Published by Elsevier Inc. doi: /j.fertnstert
2 treatment outcome in both step-down and low-dose step-up regimens and make this treatment safer and more efficient. Clinicians who prefer to use a low-dose step-up regimen may start with a higher FSH starting dose in patients with a predicted high FSH threshold. These patients may reach adequate ovarian stimulation in a shorter time and have fewer requirements for ovarian response monitoring and fewer gonadotropin preparations administered at doses below the FSH threshold. In contrast, women with a low predicted FSH threshold may start with a lower initial dose of FSH to minimize complication or cancelation rates, especially when a step-down protocol is applied. A model has previously been developed to predict the individual FSH response dose for gonadotropin induction of ovulation (20). This model includes body mass index, response to CC, baseline FSH level, and free insulin growth factor I (IGF-I). Free IGF-I however, is not measured in daily clinical practice. The FSH response dose formula in which free IGF-I was substituted by the insulin-to-glucose ratio resulted in a slightly lower predictive probability (apparent R 2 of 0.49 compared with 0.54, optimism corrected 0.34 compared with 0.39). A model that performs well in an internal validation can produce poor predictions in other patients (21). Therefore, the aim of the present study was to externally validate the response dose estimation model. We assessed the model in women with PCOS that had been treated in other centers in which the model had not been developed. METHODS Between February 1998 and October 2000, 85 women underwent ovulation induction with recombinant (r) FSH as part of a multicenter controlled trial (22). The Institutional Review Boards of all 29 participating hospitals approved the study, and written informed consent was obtained from each participant. Polycystic ovary syndrome was diagnosed on the basis of chronic anovulation and the presence of polycystic ovaries on transvaginal ultrasonography, which is in line with a recent consensus on diagnostic criteria (23, 24). All women were CC resistant, i.e., persistent anovulation was observed despite 150 mg CC daily for 5 days during a given cycle. Anovulation was defined as absent follicle development assessed by ultrasonography for 35 days. The primary exclusion criteria were other causes of infertility, such as hyperprolactinemia, hypothalamic amenorrhea, premature ovarian failure, a negative post-coital test, ovarian tumor, previous treatment with gonadotropins, age above 40 years, and a partner with male subfertility. We defined male subfertility as a semen analysis that did not meet the World Health Organization criteria for concentration, motility, and/or morphology (25). An initial clinical, ultrasonographic, and endocrinologic evaluation took place before ovulation induction with rfsh. Clinical variables studied were age, menarche, duration of infertility, cycle history (amenorrhea or oligomenorrhea), body mass index (BMI), and waist-to-hip ratio (WHR). Oligomenorrhea was defined as cycle length of more than 35 days but less than 6 months and amenorrhea was defined as intervals between periods of more than 6 months. Endocrine evaluation included serum assays for FSH, LH, E 2,T,androstenedione, sex hormone binding globulin (SHBG), fasting insulin, glucose, and leptin. The free androgen index (FAI) was calculated as T 100/SHBG. Blood samples were centrifuged within 2 hours after withdrawal and stored at 20 C until assayed. All hormone assays were performed at a single laboratory (Endocrinology Department, Academic Medical Center Amsterdam) on cryopreserved blood. The rfsh (follitropin alpha, Gonal-F; Serono Benelux, The Hague, The Netherlands) was administered in a chronic low-dose step-up protocol. The rfsh starting dose was not based on the FSH response dose as predicted by the model. Treatment started on cycle day 3 of a progesterone-induced bleeding with daily 75 IU SC injections in all women (26). Follicle development was assessed by transvaginal ultrasonography at weekly intervals or more frequently if indicated by follicle growth. If the diameter of the follicles remained at 10 mm, the dose was increased with 37.5 IU FSH on cycle day 16. In the absence of follicle growth the FSH dose was subsequently increased on cycle days 23 and 30. If still no follicle development (i.e., no follicle with a diameter of 10 mm) was seen on cycle day 35 with a maximum FSH dose of IU per day, the cycle was canceled because of poor response. Primary outcome is the FSH dose on the day of ovarian response (the FSH response dose), defined as follicle growth of 10 mm in diameter. Development Sample The population sample in which the prognostic model was developed consisted of 90 women attending the infertility unit at the Erasmus University Medical Center in Rotterdam, The Netherlands. Women that were treated between June 1997 and September 1999 were included. Women had oligoor amenorrhea, normal serum FSH level (1 10 IU/L), normal serum PRL and TSH levels, spontaneous menses or positive bleeding response to progestogen withdrawal, BMI of at least 18 kg/m 2, age of years, and previously unsuccessful treatment with CC (failure to ovulate or failure to conceive in six CC cycles that produced ovulation). The Erasmus University Medical Center did not participate in the study that provided the validation sample. Thus the model was assessed in women that had been treated in other centers than the center where the model had been developed. Data Analysis Differences in clinical, ultrasonographic, and endocrinologic parameters between the validation sample and the develop- Fertility and Sterility 1711
3 ment model (17) were tested by t tests for continuous variables and chi-squared tests for categoric variables. The prognostic effects of the patient characteristics included in the model were studied in the validation sample using linear regression with FSH response dose as the dependant variable. The formula of the model was: FSH response dose (75 to 187 IU/day) before initiation of therapy [3.5 BMI (in kg/m 2 )] [35.6 CC resistance (yes 1orno 0)] [2.6 initial free IGR] [6.7 initial serum FSH level (in IU/L)] The predicted response dose was calculated for each woman of the validation sample. Calibration was assessed by graphically plotting the observed FSH response dose against the predicted FSH response dose. The overall predictive performance (goodness of fit) of the model in the validation sample was assessed by using the multiple R 2 value. This number expresses the fraction of the total variance of FSH response dose that is explained by the regression model. The accuracy or average error of the model when used for prediction of the FSH response dose of new patients was assessed by using the root mean squared error. Data were analyzed using SPSS (SPSS, Chicago, IL) and S-PLUS 2000 (MathSoft, Cambridge, MA). RESULTS The cohort of 90 women in whom the prognostic model for response dose had been made (development sample) consisted of 40 women (44%) that did not ovulate on 150 mg CC and 50 women (56%) that did ovulate on CC but did not conceive in six CC cycles that produced ovulation (20). The population of 85 women in whom the model was validated (validation model) consisted only of women that did not ovulate on CC. Of the total of 85 women, 81 had ovarian response during their first ovulation induction cycle, defined as follicle growth of 10 mm in diameter. In 4 women the cycle was canceled owing to understimulation. In these women a next cycle was used to determine their response dose. Baseline characteristics in the 90 women who did not ovulate or conceive with CC (development sample) and in the 85 CC-resistant women with PCOS (validation sample) are presented in Table 1. The clinical characteristics appear comparable in both populations, except for hyperandrogenism. The validation population presented with higher LH, T, SHBG, FAI, and leptin levels. The FSH response dose was the dose at which ongoing dominant follicle growth beyond 10 mm was visualized. The response dosages in the development sample and the valida- TABLE 1 Women s characteristics in the development sample (n 90) a and in the validation sample (n 85). Characteristics Development sample, mean (SD) Validation sample, mean (SD) P value b Clinical Age, yrs 29 (4) 28.5 (4.1) NS Infertility duration, yrs ND 2.8 (2.2) NS Primary infertility, n (%) 66 (73%) 65 (76%) NS Amenorrhea, n (%) 37 (33%) 23 (27%) NS Body mass index, kg/m (5.5) 27.0 (5.8) NS Waist-to-hip ratio 0.81 (0.08) 0.83 (0.08) NS Ultrasound Mean ovarian volume, ml 10.7 (4.2) 11.6 (6.5) NS Endocrinology LH 8.1 (5.7) 11 (5.1).01 FSH 5.1 (1.5) 6.0 (1.6) NS T, nmol/l 2.5 (1.0) 3.9 (1.3).01 SHBG, nmol/l 48 (25) 40 (21).01 FAI 7.1 (5.4) 13.3 (10.2).001 Androstenedione, nmol/l 13.9 (6.7) 11.9 (4.3) NS Insulin, mu/l 12.3 (8.2) 10.4 (8.0) NS Glucose, mmol/l 4.3 (0.7) 5.1 (1.3) NS Insulin-to-glucose ratio, ( (2.1) 2.1 (1.7) NS Leptine, ng/ml 20 (15) 26 (18).01 a Reference 20. NS not significant. van Wely. Validation of FSH response model in PCOS. Fertil Steril van Wely et al. Validation of FSH response model in PCOS Vol. 86, No. 6, December 2006
4 TABLE 2 FSH response dose in the development sample and the validation sample. Response dose Development sample, n (%) Validation sample, n (%) 75 IU/d 33 (37) 26 (31) IU/d 27 (30) 26 (31) 150 IU/d 16 (18) 27 (32) IU/d 10 (11) 6 (7) IU/d 4 (4) van Wely. Validation of FSH response model in PCOS. Fertil Steril tion sample are listed in Table 2. In the development sample, more women received an FSH dose above 150 IU/day than in the validation sample; furthermore, the maximum dose was higher in the development sample. The observed and predicted FSH response doses obtained by using the model is visualized in a spline plot with 95% confidence intervals (Fig. 1). Overall the predicted response dose by the model was higher than the observed response, with a mean difference of 25 IU (95% CI 18 to 33). This was, however, not a systematic difference. The overestimation in predicted response dose increased with observed response dose, i.e., it was lowest at observed response doses of 75 to 100 IU and highest at the maximum observed response dose of 187 IU. The intercept of the spline was 43 IU and the slope was The R 2 of the model was 0.11, and the average prediction error (root mean squared error) was 35. This means that in the validation sample the model could explain only 11% of the between-woman variability in FSH response dose and that the standard error of the predicted value was about 35 IU/L. DISCUSSION We assessed the validity of a model predicting the individual FSH response dose for gonadotropin induction of ovulation in a low-dose step-up regimen in a comparable PCOS population different from the sample of patients used to develop the model. This study shows that the model overestimated the FSH response dose. The model predicted an FSH response dose that was on average 25 IU higher than the observed response dose. The overestimation enlarged with increasing predicted FSH response dose. The difference between predicted and observed response dose could be due to a difference in the dosing scheme or minor differences in the studied populations. Although in the validation sample the starting dose was similar to that in the development sample (75 IU/day), the first increase was performed not earlier than after 14 days of treatment, whereas in the development sample the dose was increased after 7 days. The predictive performance of the model was poor. Only 11% of the variance of FSH response dose could be explained by the regression model, which is much lower than the 34% explained variation in development data. A reason for this difference may be that in the present data only women who did not ovulate with CC were included, whereas the development study also included women that did ovulate on CC but did not conceive. Although this difference was controlled for with CC resistance as part of the model, the development data have a wider clinical scope with more variation to be explained. Although in the development sample FSH level was a predictor, in the validation sample no association between FSH level and FSH response dose was found. Of the four predictors in the model BMI, IGR, FSH level, and CC resistance only BMI and IGR were found to be associated with the FSH response dose in the validation sample. The development sample was less hyperandrogenemic than the validation sample, i.e., the validation population presented with higher LH, T, SHBG, FAI, and leptin levels. Therefore we also checked whether these factors were associated with FSH response dose in the validation sample using univariable and multivariable linear regression analysis. As in the development sample, neither FAI nor the LH, T, SHBG, or leptin levels came out as a predictor in the validation sample. The endocrinologic differences between the two populations can therefore not explain the poor predictive performance of the model. In the development sample, the starting dose was 75 IU urinary FSH in 76 women and 50 IU rfsh in 14 women. The lower dose of rfsh was used because at the time the model was developed it was thought that less rfsh was needed owing to its higher biopotency. Correction for this difference in starting dose did not affect the predictive performance of the model: The R 2 of the model remained 0.11, and the FIGURE 1 Calibration (spline) curve with confidence intervals for the regression line. van Wely. Validation of FSH response model in PCOS. Fertil Steril Fertility and Sterility 1713
5 average prediction error (root mean squared error) was 32 instead of 35. The aim of the chronic low-dose step-up regimen is to administer the lowest possible daily dose of exogenous gonadotropins to gradually surpass the individual FSH threshold to achieve follicular maturation and subsequent ovulation. The concept behind this aim is that each woman has a given threshold requirement for FSH below which follicles do not develop (27). If we are able to predict individual FSH thresholds this would increase the safety, efficiency, and convenience of low-dose regimens for gonadotropin induction of ovulation by determining the appropriate starting dose for a given patient. Time-consuming low-dose increases in dosage may be avoided by starting with a higher dose in women with a high FSH threshold. In addition, starting with an individualized dose in step-down regimens may reduce chances for hyperresponse in women with a low FSH threshold. However, a model that predicts response doses that are higher than the real response doses, as we found in our validation sample, is not useful. Even more, implementing this exact model could in theory lead to more cancelations, ovarian hyperstimulation syndrome, and multiple pregnancies, i.e., the opposite of what the model aimed for. It is possible that the model performs better in a population that undergoes ovarian stimulation with a starting dose of 75 IU and a dose increase after 7 days. However, the state-of-the-art regimen uses a chronic low-dose step-up scheme with a dose increase not earlier than after 14 days (7, 22, 27). Furthermore, in highly responsive women with PCOS the risk of multiple follicular development and multiple pregnancies can in theory be prevented when lower starting doses are used. Available data suggest that similar pregnancy rates can be obtained when starting with doses from 25 to 37.5 IU and using smaller incremental doses (26, 28). We therefore challenge investigators to develop a new model in women with CC-resistant PCOS that are undergoing a chronic low dose step-up protocol with a starting dose below 75 IU. We conclude that the external validity of the model predicting the individual FSH response dose was inadequate in women with CC-resistant PCOS undergoing ovulation induction with rfsh in a low-dose step-up regimen. REFERENCES 1. Hull MG. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol 1987; 1: Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83: DiamantiKandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84: Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar- Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85: Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab 1998;83: Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril 2002;77: Christin-Maitre S, Hugues JN. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum Reprod 2003;18: Eijkemans MJ, Imani B, Mulders AG, Habbema JD, Fauser BC. High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2). Hum Reprod 2003;18: van Wely M, Yding AC, Bayram N, van der Veen F. Urofollitropin and ovulation induction. Treat Endocrinol 2005;4: Homburg R. Management of infertility and prevention of ovarian hyperstimulation in women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18: van Santbrink EJ, Eijkemans MJ, Laven JS, Fauser BC. Patient-tailored conventional ovulation induction algorithms in anovulatory infertility. Trends Endocrinol Metab 2005;16: Fauser BC, Devroey P, Macklon NS. Multiple birth resulting from ovarian stimulation for subfertility treatment. Lancet 2005;365: Brown JB. Pituitary control of ovarian function concepts derived from gonadotrophin therapy. Aust N Z J Obstet Gynaecol 1978;18: Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002;8: Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 2003;9: van Santbrink EJ, Donderwinkel PF, van Dessel TJ, Fauser BC. Gonadotrophin induction of ovulation using a step-down dose regimen: single-centre clinical experience in 82 patients. Hum Reprod 1995;10: van Santbrink EJ, Fauser BC. Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: prospective, randomized comparison between low dose step-up and stepdown dose regimens. J Clin Endocrinol Metab 1997;82: Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 1997;18: van Santbrink EJ, Hop WC, van Dessel TJ, de Jong FH, Fauser BC. Decremental follicle-stimulating hormone and dominant follicle development during the normal menstrual cycle. Fertil Steril 1995;64: Imani B, Eijkemans MJ, Faessen GH, Bouchard P, Giudice LC, Fauser BC. Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency. Fertil Steril 2002;77: Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med 1999;130: Bayram N, Van Wely M, Kaaijk EM, Bossuyt PM, van der Veen F. Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. BMJ 2004;328: Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term 1714 van Wely et al. Validation of FSH response model in PCOS Vol. 86, No. 6, December 2006
6 health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19: WHO manual for the standardized investigation and diagnosis of the infertile couple. Cambridge: Cambridge University Press, White DM, Polson DW, Kiddy D, Sagle P, Watson H, Gilling-Smith C, et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab 1996;81: Homburg R, Howles CM. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum Reprod Update 1999;5: Balasch J, Fabregues F, Creus M, Casamitjana R, Puerto B, Vanrell JA. Recombinant human follicle-stimulating hormone for ovulation induction in polycystic ovary syndrome: a prospective, randomized trial of two starting doses in a chronic low-dose step-up protocol. J Assist Reprod Genet 2000;17: Fertility and Sterility 1715
Gonadotrophin treatment in patients with Polycystic Ovary Syndrome
Int. J. Adv. Res. Biol. Sci. (218). 5(4): 95-99 International Journal of Advanced Research in Biological Sciences ISSN: 2348-869 www.ijarbs.com DOI: 1.22192/ijarbs Coden: IJARQG(USA) Volume 5, Issue 4-218
More informationIndividualized cost-effective conventional ovulation induction treatment in normogonadotrophic anovulatory infertility (WHO group 2)
Human Reproduction Page 1 of 8 Hum. Reprod. Advance Access published July 8, 2005 doi:10.1093/humrep/dei164 Individualized cost-effective conventional ovulation induction treatment in normogonadotrophic
More informationArticle Prediction of chances for success or complications in gonadotrophin ovulation induction in normogonadotrophic anovulatory infertility
RBMOnline - Vol 7. No 2. 170 178 Reproductive BioMedicine Online; www.rbmonline.com/article/919 on web 26 May 2003 Article Prediction of chances for success or complications in gonadotrophin ovulation
More informationThe basic fertility workup in women with polycystic ovary syndrome: a systematic review
The basic fertility workup in women with polycystic ovary syndrome: a systematic review Marleen J. Nahuis, M.D., a,b,c G. Jurjen E. Oosterhuis, M.D., b Peter G. A. Hompes, M.D., c Madelon van Wely, M.D.,
More informationA. Leader, M.D., for the Monofollicular Ovulation Induction Study Group
Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low-dose step-up protocol with weekly increments of 25 international units of follicle-stimulating hormone A. Leader, M.D.,
More informationStudy population The hypothetical study population comprised women with WHO 2 anovulatory infertility.
Individualized cost-effective conventional ovulation induction treatment in normogonadotrophic anovulatory infertility (WHO group 2) Eijkemans M J, Polinder S, Mulders A G, Laven J S, Habbema J D, Fauser
More informationDiagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome
Endocrine Journal 2007, 54 (2), 233 238 Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome TAKESHI IWASA, TOSHIYA MATSUZAKI, MASAHIRO MINAKUCHI, NAOKO
More informationPrevalence of polycystic ovarian syndrome in the Buraimi region of Oman
Original Article Brunei Int Med J. 2012; 8 (5): 248-252 Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman Usha VARGHESE 1 and Shaji VARUGHESE 2, 1 Department of Internal Medicine
More informationA comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome
Human Reproduction Vol.18, No.8 pp. 1626±1631, 2003 DOI: 10.1093/humrep/deg336 A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome S.Christin-Maitre
More informationclinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome
& clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome Zulfo Godinjak¹*, Ranka Javorić² 1 Gynecology and Obstetrics
More informationNature and Science 2017;15(8)
Prognostic Value of Day 3 Luteinising Hormone (LH) in the prediction of Ovarian Response in Patients with Polycystic Ovary syndrome Mohammed Samir Fouad 1 ; Mohammed Said El-Shorbagy 2, Mohammed Mohammed
More informationORIGINAL ARTICLE Reproductive endocrinology
Human Reproduction, Vol.26, No.7 pp. 1899 1904, 2011 Advanced Access publication on May 15, 2011 doi:10.1093/humrep/der141 ORIGINAL ARTICLE Reproductive endocrinology Long-term outcomes in women with polycystic
More informationMETABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY
Vuk Vrhovac University Clinic Dugi dol 4a, HR-10000 Zagreb, Croatia Original Research Article Received: February 18, 2010 Accepted: March 3, 2010 METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN
More informationDetermining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs)
Abstract: Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs) Ashraf Olabi, Ghena Alqotini College of medicine, Aleppo University Hospital Obstetrics and Gynacology, Syria.
More informationwww.iffs-reproduction.org @IntFertilitySoc Int@FedFertilitySoc Conflict of interest none Outline Causes of ovulatory dysfunction Assessment of women with ovulatory dysfunction Management First line Second
More informationOutlook Gonadotrophin treatment in patients with polycystic ovary syndrome
RBMOnline - Vol 8. No 5. 2004 528-537 Reproductive BioMedicine Online; www.rbmonline.com/article/1264 on web 2 March 2004 Outlook Gonadotrophin treatment in patients with polycystic ovary syndrome Dr Hakan
More informationArticle Ovulation induction using low-dose step-up rfsh in Vietnamese women with polycystic ovary syndrome
RBMOnline - Vol 18. No 4. 2009 516-521 Reproductive BioMedicine Online; www.rbmonline.com/article/3636 on web 19 February 2009 Article Ovulation induction using low-dose step-up rfsh in Vietnamese women
More informationIVM in PCOS patients. Introduction (1) Introduction (2) Michael Grynberg René Frydman
IVM in PCOS patients Michael Grynberg René Frydman Department of Obstetrics and Gynecology A. Beclere Hospital, Clamart, France Maribor, Slovenia, 27-28 February 2009 Introduction (1) IVM could be a major
More informationThe prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria
Prace oryginalne/original papers Endokrynologia Polska/Polish Journal of Endocrinology Tom/Volume 62; Numer/Number 3/2011 ISSN 0423 104X The prevalence of polycystic ovary syndrome in Iranian women based
More informationIn Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome
Original Article Effect of Laparoscopic Ovarian Drilling on Outcomes of In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Maryam Eftekhar, M.D. 1, Razieh Deghani Firoozabadi,
More informationCan Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?
www.ijpm.in www.ijpm.ir Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome? Ferdous Mehrabian, Maryam Afghahi Department
More informationPredicting the FSH threshold dose in women with WHO Group II anovulatory infertility failing to ovulate or conceive on clomiphene citrate
Human Reproduction Vol.23, No.6 pp. 1424 1430, 2008 Advance Access publication on March 26, 2008 doi:10.1093/humrep/den089 Predicting the FSH threshold dose in women with WHO Group II anovulatory infertility
More informationOriginal Article. Fauzia HaqNawaz 1*, Saadia Virk 2, Tasleem Qadir 3, Saadia Imam 3, Javed Rizvi 2
Original Article Comparison of Letrozole and Clomiphene Citrate Efficacy along with Gonadotrophins in Controlled Ovarian Hyperstimulation for Intrauterine Insemination Cycles Fauzia HaqNawaz 1*, Saadia
More informationLow-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements
Human Reproduction Update 1999, Vol. 5, No.5 p. 493 499 European Society of Human Reproduction and Embryology Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome:
More information- Meta. : (rfsh); (ufsh); (IVF); : R711.6 : A : X(2015) : hmg( FSH LH) [ufsh, (ufsh-p) (ufsh-hp)] (rfsh) [1] 80, rfsh, 90, :
35 2 Vol.35 No.2 2015 2 Feb. 2015 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2015.02.0099 E-mail: randc_journal@163.com (FSH) - Meta FSH ( 400010) : (IVF) (ICSI) (rfsh) (ufsh) (COS) : PubMed
More informationPrevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study
Prevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study Mousa Mohsen Ali* Wasan Ghazi* HayderAamerAbboud^ *Kerbala University, College of Medicine, Gynecology
More information3. Metformin therapy for PCOS
1. Introduction The key clinical features of polycystic ovary syndrome (PCOS) are hyperandrogenism (hirsutism, acne, alopecia) and menstrual irregularity with associated anovulatory infertility. 1 The
More informationResearch and Clinical Center for Infertility, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran
An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate metformin in patients with polycystic ovary syndrome Mohammad Ali Karimzadeh
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Definition: the diagnostic criteria Evidence of hyperandrogenism, biochemical &/or clinical (hirsutism, acne & male pattern baldness). Ovulatory dysfunction; amenorrhoea; oligomenorrhoea
More informationIVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)
34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh
More informationlbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour
lbt lab tests t and Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour Research Instituteof Avicenna 4/23/2012 Why good prediction of poor response good prediction i of OHSS application appropriate
More informationClinical, biochemical and ultrasonographic characteristics of Scandinavian women with PCOS
Acta Obstet Gynecol Scand 2004: 83: 482--486 Copyright # Acta Obstet Gynecol Scand 2004 Printed in Denmark. All rights reserved Acta Obstetricia et Gynecologica Scandinavica ORIGINAL ARTICLE Clinical,
More informationHum. Reprod. Advance Access published July 27, 2006
Human Reproduction Page 1 of 6 Hum. Reprod. Advance Access published July 27, 2006 doi:10.1093/humrep/del265 The use of a decremental dose regimen in patients treated with a chronic low-dose step-up protocol
More informationOverview of Reproductive Endocrinology
Overview of Reproductive Endocrinology I have no conflicts of interest to report. Maria Yialamas, MD Female Hypothalamic--Gonadal Axis 15 4 Hormone Secretion in the Normal Menstrual Cycle LH FSH E2, Progesterone,
More informationPolycystic Ovary Syndrome (PCOS):
Polycystic Ovary Syndrome (PCOS): Current diagnosis and treatment Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the end of this presentation,
More informationComparison of different starting gonadotropin doses (50, 75 and 100 IU daily) for ovulation induction combined with intrauterine insemination
Arch Gynecol Obstet (2012) 286:1055 1059 DOI 10.1007/s00404-012-2414-3 REPRODUCTIVE MEDICINE Comparison of different starting gonadotropin doses (50, 75 and daily) for ovulation induction combined with
More information2017 United HealthCare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1143-4 Program Prior Authorization/Notification Medication Menopur (menotropins) * P&T Approval Date 8/2014, 5/2015, 5/2016, 5/2017
More informationAims of this talk. Evaluation & investigation. Basic treatments/options including ovulation induction & Intra uterine Insemination
Basic treatments/options including ovulation induction & Intra uterine Insemination Karen Woodcock Clinical Nurse Specialist/ Nurse Manager Fertility & Assisted Conception Unit Countess of Chester NHS
More informationPolycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More informationStudentoppgave. Veileder: Dr. med Jan Mellembakken, overlege Kvinneklinikken, Rikshospitalet. Profesjonsstudiet i Medisin
Studentoppgave Maintained number of oocytes with advanced age in PCOS women during IVF treatment compared to controls Mirjam Kilen Veileder: Dr. med Jan Mellembakken, overlege Kvinneklinikken, Rikshospitalet
More informationCOMPARING AMH, AFC AND FSH FOR PREDICTING HIGH OVARIAN RESPONSE IN WOMEN UNDERGOING ANTAGONIST PROTOCOL
COMPARING AMH, AFC AND FSH FOR PREDICTING HIGH OVARIAN RESPONSE IN WOMEN UNDERGOING ANTAGONIST PROTOCOL Nguyen Xuan Hoi1, Nguyen Manh Ha2 1 National Obstetrics and Gynecology Hospital, 2Hanoi Medical Unviversity
More informationDoes free androgen index predict subsequent pregnancy outcome in women with recurrent miscarriage?
Human Reproduction Vol.23, No.4 pp. 797 802, 2008 Advance Access publication on February 8, 2008 doi:10.1093/humrep/den022 Does free androgen index predict subsequent pregnancy outcome in women with recurrent
More informationPCOS What s new in Diagnosis & Treatment?
PCOS What s new in Diagnosis & Treatment? Roy Homburg Maccabi Medical Services and Barzilai Medical Centre, Ashkelon, Israel. Antalya, October, 2009 PCOS diagnosis - 1990 NIH criteria - Hyperandrogenism
More informationInfertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary
Subfertility Infertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary Infertility affects about 15 % of couples. age of the female. Other factors that
More informationNeil Goodman, MD, FACE
Initial Workup of Infertile Couple: Female Neil Goodman, MD, FACE Professor of Medicine Voluntary Faculty University of Miami Miller School of Medicine Scope of Infertility in the United States Affects
More information12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman
Polycystic Ovarian Syndrome (PCOS) for the Family Physician Barbara S. Apgar MD, MS Professor or Family Medicine University of Michigan Ann Arbor, Michigan Important references for PCOS Endocrine Society
More informationApproach to ovulation induction and superovulation in women with a history of infertility. Anatte E. Karmon, MD
Approach to ovulation induction and superovulation in women with a history of infertility Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the
More informationDoes previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?
J Assist Reprod Genet (26) 23:427 431 DOI 1.17/s1815-6-965-x ASSISTED REPRODUCTION Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation
More informationOriginal Investigation. 94 Endocrine Oncology and Metabolism. Jovanovska et al
Original Investigation Sensitivity and specificity of anti-mülerian hormone in the diagnosis of polycystic ovary syndrome in a macedonian population of women of reproductive age: a cross-sectional study
More informationReproductive FSH. Analyte Information
Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary
More informationS. AMH in PCOS Research Insights beyond a Diagnostic Marker
S. AMH in PCOS Research Insights beyond a Diagnostic Marker Dr. Anushree D. Patil, MD. DGO Scientist - D National Institute for Research in Reproductive Health (Indian Council of Medical Research) (Dr.
More informationX/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Copyright 2006 by The Endocrine Society doi: /jc.
0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Printed in U.S.A. Copyright 2006 by The Endocrine Society doi: 10.1210/jc.2005-1457 EXTENSIVE CLINICAL EXPERIENCE Relative
More informationNew York Science Journal 2017;10(8)
Clomiphene Citrate Stair Step Protocol with Phytoestrogen Vs. Traditional Protocol in Patient with Polycystic Ovary Syndrome Asem A. Mousa (MD) 1, Mohamed A. Mohamed (MD) 1, Waleed A. Saad (MBBCH) 2 2
More informationClinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients
International Reproductive Medicine Volume 2013, Article ID 135258, 4 pages http://dx.doi.org/10.1155/2013/135258 Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin
More informationAIMS To evaluate the effectiveness and safety of laparoscopic ovarian drilling compared with ovulation induction for clomiphene-resistant PCOS.
LAPAROSCOPIC OVARIAN DRILLING Dr.Shiraaz Shaikh Khalil, M.B.B.S, DGO, MD, D.MAS Obstetrician and Gynecologist Member of World Association of Laparoscopic Surgeons ABSTRACT First established treatment for
More informationInfluence ovarian stimulation on oocyte and embryo quality. Prof.Dr. Bart CJM Fauser
Influence ovarian stimulation on oocyte and embryo quality Prof.Dr. Bart CJM Fauser How to balance too much vs too little? Lecture Outline Context ovarian stimulation Impact ovarian stimulation on oocyte
More information2013 Sep.; 24(3):
Journal of Reproduction & Contraception doi: 10.7669/j.issn.1001-7844.2013.03.0159 2013 Sep.; 24(3):159-172 E-mail: randc_journal@163.com Comparison of the Effects and Safety of Mild Ovarian Stimulation
More informationUterus & Ovary 2015; 2: e904. doi: /uo.904; 2015 by Ahmed M Maged, et al.
RESEARCH ARTICLE Phytoestrogens as an alternative to estradiol in reversing the antiestrogenic effect of clomid on endometrium in ovulation induction in cases of polycystic ovarian syndrome (PCOS) Ahmed
More informationPersonalizing ovarian stimulation for IVF
Personalizing ovarian stimulation for IVF Biljana Popovic-Todorovic MD,PhD Centre for Reproductive Medicine UZ Brussel QuickTime and are needed to see this picture. Controlled ovarian stimulation for IVF/ICSI
More informationNew PCOS guidelines: What s relevant to general practice
New PCOS guidelines: What s relevant to general practice Dr Michael Costello Fertility Specialist IVF Australia UNSW Royal Hospital for Women Sydney How do we know if something is new? Louvre Museum, Paris
More informationEffect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 71, NO. 2, FEBRUARY 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effect of troglitazone
More informationClomiphene stair-step protocol for ovulation induction in women with polycystic ovarian syndrome *
Clomiphene stair-step protocol for ovulation induction in women with polycystic ovarian syndrome * Basima Al Ghazali Abstract The objective of this study is to evaluate the efficacy of the clomiphene stair-step
More informationJMSCR Vol 05 Issue 05 Page May 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.14 Hyperinsulinemia in Polycystic Ovary Syndrome
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Recombinant versus urinary follicle-stimulating hormone in intrauterine insemination cycles: a prospective, randomized analysis of cost effectiveness Gerli S, Casini M L, Unfer V, Costabile L, Bini V,
More informationLuteal phase rescue after GnRHa triggering Progesterone and Estradiol
Luteal phase rescue after GnRHa triggering Progesterone and Estradiol L. Engmann University of Connecticut Disclaimer Fertility Speaker Bureau Merck Pharmaceuticals Introduction GnRH agonist is effective
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome What is Polycystic Ovarian Syndrome? Polycystic Ovarian Syndrome (PCOS) is characterized by the presence of multiple ovarian cysts and excess androgen production. Clinical Features
More informationUnderstanding Infertility, Evaluations, and Treatment Options
Understanding Infertility, Evaluations, and Treatment Options Arlene J. Morales, M.D., F.A.C.O.G. Fertility Specialists Medical Group, Inc. What We Will Cover Introduction What is infertility? Briefly
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationMinimal stimulation protocol for use with intrauterine insemination in the treatment of infertility Dhaliwal L K, Sialy R K, Gopalan S, Majumdar S
Minimal stimulation protocol for use with intrauterine insemination in the treatment of infertility Dhaliwal L K, Sialy R K, Gopalan S, Majumdar S Record Status This is a critical abstract of an economic
More informationClinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes
POLYCYSTIC OVARY SYNDROME Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes Ettore Guastella, M.D., a Rosa Alba Longo, M.D., b and Enrico Carmina, M.D. b a Department
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 22 September 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 September 2010 100 µg/0.5 ml, solution for injection B/1 prefilled syringe + 1 needle (CIP code: 374 590-1) 150
More informationROLE OF METFORMIN IN POLYCYSTIC OVARIAN SYNDROME
ORIGINAL ARTICLE ROLE OF METFORMIN IN POLYCYSTIC OVARIAN SYNDROME 1 2 3 Samdana Wahab, Farnaz, Rukhsana Karim ABSTRACT Objective: To assess the role of Metformin in Polycystic ovarian syndrome (PCOS).
More informationDiabetic Medicine. Myo-inositol may prevent gestational diabetes in PCOS women. Preliminary data.
Myo-inositol may prevent gestational diabetes in PCOS women. Preliminary data. Journal: Diabetic Medicine Manuscript ID: DME--00 Manuscript Type: Short Report Date Submitted by the Author: -May- Complete
More informationWHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED
WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED Ricardo Azziz, M.D., M.P.H., M.B.A. Chief Officer of Academic Health & Hospital Affairs State University of New York (SUNY)
More informationNew York Science Journal 2017;10(7)
Comparative Study between Letrozole and Tamoxifen Citrate in Treatment of Clomiphene Citrate Resistant Polycystic Ovarian Syndrome Farid Ibrahim Hassan, Abd Allah Khalil Ahmed, Abd El Raouf Abd El Raouf
More informationKey words: laparoscopic ovarian multiple punch resection, laparoscopic ovarian electrocautery, infertility,
Key words: laparoscopic ovarian multiple punch resection, laparoscopic ovarian electrocautery, infertility, polycystic ovarian syndrome, clomiphene citrate 1) Insler V, Zakut H, Serr M. Cycle pattern
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationThe serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins
Original Article Obstet Gynecol Sci 2018;61(2):242-246 https://doi.org/10.5468/ogs.2018.61.2.242 pissn 2287-8572 eissn 2287-8580 The serum estradiol/oocyte ratio in patients with breast cancer undergoing
More informationInfertility: A Generalist s Perspective
Infertility: A Generalist s Perspective Learning Objectives Fertility and Lifestyle: Patient education Describe the basic infertility workup Basic treatment strategies unexplained Heather Huddleston, MD
More informationWhat every dermatologist should know about Polycystic Ovary Syndrome (PCOS)
What every dermatologist should know about Polycystic Ovary Syndrome (PCOS) Kanade Shinkai, MD PhD University of California, San Francisco Associate Professor of Dermatology I have no conflicts of interest
More informationPCOS. Reproductive Gynaecology and Infertility. Dr.Renda Bouzayen MD.FRCSC GREI,OBGYN Dalhousie University
Reproductive Gynaecology and Infertility PCOS Dr.Renda Bouzayen MD.FRCSC GREI,OBGYN Dalhousie University Dr.Hussein Sabban MD. FRCSC PGY6 GREI Dalhousie University Disclosure No conflict of interest Pilot
More informationPolycystic Ovary Disease: A Common Endocrine Disorder in Women
Polycystic Ovary Disease: A Common Endocrine Disorder in Women Paul Kaplan, M.D. Clinical Professor of Reproductive Endocrinology - OHSU Courtesy Senior Research Associate, Human Physiology University
More informationPOLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility. Based on: ACOG No. 108 Oct 2009; reaffirmed 2015
POLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility Based on: ACOG No. 108 Oct 2009; reaffirmed 2015 NO DISCLOSURES PATIENT 26 years old presents with complaint of
More informationAchieving Pregnancy: Obesity and Infertility. Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center
Achieving Pregnancy: Obesity and Infertility Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center Disclosures Speakers Bureau EMD Serono Board of Directors Nurse
More informationObjectives 06/21/18 STILL A PLACE FOR PILLS DON T IVF EVERYTHING. Clomiphene citrate and Letrozole. Infertility Case Studies. Unexplained Infertility
STILL A PLACE FOR PILLS DON T IVF EVERYTHING Jeff Roberts M.D. Co-Director, Pacific Centre for Reproductive Medicine Objectives 1 2 3 4 5 Clomiphene citrate and Letrozole Infertility Case Studies Unexplained
More informationIntroduction. Original Article
Iran J Reprod Med Vol. 10. No. 4. pp: 307-314, July 2012 Original Article Correlation of biochemical markers and clinical signs of hyperandrogenism in women with polycystic ovary syndrome (PCOS) and women
More informationPage 196. Corresponding Author: Swati Garg, Volume 3 Issue - 4, Page No
ISSN- O: 2458-868X, ISSN P: 2458 8687 Index Copernicus Value: 49. 23 SJIF Impact Factor: 4.271 International Journal of Medical Science and Innovative Research (IJMSIR) IJMSIR : A Medical Publication Hub
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationJournal of American Science 2013;9(12)
Early Clomiphene Citrate for Induction of Ovulation in Women with Polycystic Ovary Syndrome a randomized controlled trial Elguindy A. 1, Hussein M. 1 * and El-Shamy R 2 1 Department of Obstetrics and Gynecology,
More informationInvestigation of adrenal functions in patients with idiopathic hyperandrogenemia
European Journal of Endocrinology (26) 155 37 311 ISSN 84-4643 CLINICAL STUDY Investigation of adrenal functions in patients with idiopathic hyperandrogenemia Hulusi Atmaca, Fatih Tanriverdi 1, Kursad
More informationPrinciples of Ovarian Stimulation
Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle
More informationFertility and assisted reproduction. Introduction. AH Balen, a P Platteau, b AN Andersen, c P Devroey, b P Sørensen, d L Helmgaard, d J-C Arce d
DOI: 10.1111/j.1471-0528.2006.01034.x www.blackwellpublishing.com/bjog Fertility and assisted reproduction The influence of body weight on response to ovulation induction with gonadotrophins in 335 women
More informationGonadotrophins for ovulation induction in women with polycystic ovarian syndrome(review)
Cochrane Database of Systematic Reviews Gonadotrophins for ovulation induction in women with polycystic ovarian syndrome(review) WeissNS,NahuisM,BayramN,MolBWJ,VanderVeenF,vanWelyM WeissNS,NahuisM,BayramN,MolBWJ,VanderVeenF,vanWelyM.
More informationAcademic Sciences. Asian Journal of Pharmaceutical and Clinical Research
Academic Sciences Asian Journal of Pharmaceutical and Clinical Research Vol 5, Issue 3, 202 ISSN - 0974-244 Research Article A COMPARATIVE STUDY ON THE EFFECTIVENESS OF SINGLE AND COMBINATION THERAPIES
More informationOutlook PCOS: a diagnostic challenge
RBMOnline - Vol 8. No 6. 2004 644-648 Reproductive BioMedicine Online; www.rbmonline.com/article/1274 on web 5 April 2004 Outlook PCOS: a diagnostic challenge Dr Ricardo Azziz Dr Azziz is currently Chairman
More informationORIGINAL ARTICLE Establishing the cut off values of androgen markers in the assessment of polycystic ovarian syndrome
Malaysian J Pathol 2018; 40(1) : 33 39 ORIGINAL ARTICLE Establishing the cut off values of androgen markers in the assessment of polycystic ovarian syndrome R N Dineshinee NADARAJA MBBS, Pavai STHANESHWAR
More informationHormonal Changes After Laparoscopic Ovarian Diathermy in Patients with Polycystic Ovarian Syndrome
DOI 10.1007/s13224-016-0882-2 ORIGINAL ARTICLE Hormonal Changes After Laparoscopic Ovarian Diathermy in Patients with Polycystic Ovarian Syndrome Elsayed A. Elnaggar 1 Youssef Abo Elwan 1 Safaa A. Ibrahim
More informationAbstract. Introduction. RBMOnline - Vol 9. No Reproductive BioMedicine Online; on web 19 August 2004
RBMOnline - Vol 9. No 4. 382-390 Reproductive BioMedicine Online; www.rbmonline.com/article/1444 on web 19 August 2004 Article Ovulation induction in women with polycystic ovary syndrome: randomized trial
More informationAntim ullerian hormone and polycystic ovary syndrome
Antim ullerian hormone and polycystic ovary syndrome Yi-Hui Lin, M.D., a Wan-Chun Chiu, Ph.D., c Chien-Hua Wu, Ph.D., b,e Chii-Ruey Tzeng, M.D., d Chun-Sen Hsu, M.D., a and Ming-I Hsu, M.D. a a Department
More informationInterpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used
Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used Ellenbogen A., M.D., Shalom-Paz E., M.D, Asalih N., M.D, Samara
More information